Devices › Permanent defibrillator electrodes
Device brand name · Permanent defibrillator electrodes
Epsila EV MRI SureScan: medical device reports filed with FDA
1,869 reports name it, 2023–2026. Manufacturer given most often on reports: Medtronic Puerto Rico Villalba. Product code NVY.
- 1,869
- device reports naming the brand
- 0% of all MAUDE reports · about 702 a year
- 1,023
- reports, 12 months to August 2026
- 631 in the 12 months before
- 38.3%
- classified as malfunction
- 41.2% across the product code
- 1%
- classified as death, as reported
- 18 reports · not verified by FDA
FDA's MAUDE database holds 1,869 reports that name the brand "Epsila EV MRI SureScan" (permanent defibrillator electrodes), received between November 2023 and August 2026; the manufacturer given most often on reports is Medtronic Puerto Rico Villalba. Spellings of one product vary from report to report.
1,023 reports arrived in the 12 months to August 2026, up 62% from 631 in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are injury (60.7%), malfunction (38.3%) and death (1%); across all permanent defibrillator electrodes reports (product code NVY) death is recorded in 2.2% and malfunction in 41.2%. Event type is the reporter's classification of the report, not a verified outcome.
The device problems coded most often are over-sensing (54.9%), signal artifact/noise (39.9%) and under-sensing (17.8%). The patient problems coded most often are shock from patient lead(s), perforation and pain. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Reports by month, five years
Reports by the month FDA received them. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
By year received
Event type and report source
Event type, as classified on the report
Who filed the report
Grey bar: all 138,578 reports carrying product code NVY. Event type is the filer's classification and is not verified by FDA.
Device problems coded
| Device problem (FDA code) | Reports | Share | Share across product code |
|---|---|---|---|
| Over-sensing | 1,027 | 54.9% | 22.8% |
| Signal artifact/noise | 746 | 39.9% | 6.6% |
| Under-sensing | 332 | 17.8% | 2.5% |
| Decreased sensitivity | 302 | 16.2% | 2% |
| Inappropriate/inadequate shock/stimulation | 291 | 15.6% | 8.5% |
| Device dislodged or dislocated | 223 | 11.9% | 10.9% |
| High impedance | 126 | 6.7% | 20% |
| Impedance problem | 124 | 6.6% | 3.1% |
| Low impedance | 114 | 6.1% | 6% |
| Device sensing problem | 78 | 4.2% | 5% |
| Positioning problem | 53 | 2.8% | 0.4% |
| Failure to convert rhythm | 43 | 2.3% | 0.5% |
| Pacing problem | 25 | 1.3% | 2.1% |
| Defibrillation/stimulation problem | 24 | 1.3% | 0.4% |
| Fracturea broken bone | 22 | 1.2% | 5.4% |
| Unstable impedance | 15 | 0.8% | 0% |
| Breakthe device broke | 12 | 0.6% | 8.8% |
| High capture threshold | 12 | 0.6% | 8.1% |
| Electrical /electronic property probleman electrical or electronic problem | 10 | 0.5% | 0.1% |
| Device slipped | 8 | 0.4% | 0% |
FDA's device problem codes as entered on the report; one report can carry several. Generic codes such as "no apparent adverse event" are left out.
Patient problems coded
| Patient problem (FDA code) | Reports | Share |
|---|---|---|
| Shock from patient lead(s) | 307 | 16.4% |
| Perforation | 63 | 3.4% |
| Painpain, site not specified | 37 | 2% |
| Chest painchest pain | 36 | 1.9% |
| Discomfortdiscomfort | 35 | 1.9% |
| Erythemaskin redness | 33 | 1.8% |
| Ventricular fibrillationa chaotic rhythm from the lower heart chambers | 33 | 1.8% |
| Purulent discharge | 28 | 1.5% |
| Wound dehiscencea wound reopened | 24 | 1.3% |
| Erosion | 20 | 1.1% |
| Medical device site infectioninfection at the device site | 18 | 1% |
| Bacterial infectiona bacterial infection | 17 | 0.9% |
| Tachycardiafast heart rate | 15 | 0.8% |
| Pleural effusionfluid around the lung | 14 | 0.7% |
| Pneumothoraxa collapsed lung | 13 | 0.7% |
Patient problem codes are present mainly in reports filed since 2019 and are often blank.
In context
| Measure | Epsila EV MRI SureScan | Product code NVY | All MAUDE reports |
|---|---|---|---|
| Reports | 1,869 | 138,578 | 26,136,888 |
| Share of that pool | — | 1.3% | 0% |
| Classified as death, per 1,000 reports | 10 | 22 | 9 |
| Classified as injury | 60.7% | 56.5% | 36.2% |
| Classified as malfunction | 38.3% | 41.2% | 62.3% |
| Filed by the manufacturer | 100% | 97.3% | 94.9% |
Shares are of reports, not of devices in use. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Other brands with product code NVY
| Brand | Reports | Latest 12 months | Classified as death |
|---|---|---|---|
| Durata Sts Optim Active Fixation Df-4 Connector | 27,828 | 1,784 | 3.9% |
| Endotak Reliance | 25,897 | 238 | 1.2% |
| Riata Active Fixation | 13,753 | 96 | 1.8% |
| Sprint Quattro Secure MRI SureScan | 15,606 | 1,903 | 1.4% |
| Optisure Active Fixation Df-4 Connector | 6,562 | 623 | 4.3% |
| Endotak Reliance Sg | 8,288 | 1,083 | 0.5% |
| Sprint Quattro Secure | 24,237 | 2 | 5.2% |
| Riata St Active Fixation | 5,416 | 76 | 2.2% |
| Reliance 4-Front | 9,852 | 2,024 | 0.4% |
| Isoflex Optim Lead | 7,889 | 437 | 2% |
| Durata Sts Optim Active Fixation | 9,681 | 301 | 5.6% |
| Riata Passive Fixation | 4,318 | 32 | 1.2% |
| Endotak Reliance G | 10,115 | 1,049 | 0.6% |
| Plexa ProMRI S 65 | 2,521 | 245 | 0.6% |
| Permanent Defibrillator Electrodes | 2,524 | 230 | 0.6% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA also states that "common products may have a higher number of adverse events due to the higher total number of people using the product."
Questions about Epsila EV MRI SureScan reports
How many FDA reports name Epsila EV MRI SureScan?
1,869 medical device reports in the openFDA MAUDE release of 28 Sep 2026, covering reports received through August 2026; 1,023 in the latest 12 months.
What kinds of events are reported?
injury (60.7%), malfunction (38.3%) and death (1%). "Event type" is how the report was classified when filed: death, injury, malfunction or other.
What device problems are coded?
over-sensing (54.9%), signal artifact/noise (39.9%), under-sensing (17.8%), decreased sensitivity (16.2%) and inappropriate/inadequate shock/stimulation (15.6%). These are FDA's device problem codes as entered on the report.
Who files these reports?
manufacturer reports (100%). Manufacturers and user facilities are required to report; voluntary reports come from health professionals and the public.
Do these reports show that Epsila EV MRI SureScan was at fault?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." FDA adds that "a causal relationship cannot be established between product and reactions listed in a report."
How do I report a problem with a medical device?
Through FDA MedWatch (Form FDA 3500 for health professionals and consumers), or to the manufacturer. See the guide on how to report.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. A report counts here when any device it lists carries this brand name after punctuation and capitalisation are normalised. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.